Stereotactic Radiosurgery · Cranial
Meningioma
Excellent control for the benign, surgically difficult tumor — and why grade changes everything
For the WHO grade I meningioma in a location where surgery is morbid — the cavernous sinus, petroclival region, or other skull-base sites — radiosurgery offers durable tumor control with low cranial-nerve morbidity, often without a tissue diagnosis. The picture changes sharply with higher grade: atypical and anaplastic meningiomas behave aggressively and are managed with surgery and higher-dose, usually fractionated, radiotherapy. This page covers selection, dose, the perioptic problem, and the grade dependence.
Orientation
Most meningiomas treated with radiosurgery are presumed WHO grade I tumors diagnosed on imaging — a dural-based, homogeneously enhancing mass with a dural tail — in a location where the morbidity of resection is high. In carefully selected small tumors, especially skull-base lesions where complete resection would be morbid, SRS provides high long-term control while avoiding upfront cranial-nerve and vascular risk; it should not be read as a blanket substitute for safe resection when tissue diagnosis, decompression, or cytoreduction is needed. The two things that most change management are location relative to the optic apparatus (which caps the deliverable single-fraction dose) and histologic grade (which, when high, demands a different, more aggressive radiotherapeutic strategy). Skull-base radiosurgery, in particular, is a setting where the author's preference for Gamma Knife is reasonable but not evidence-mandated.
Selection
1.Who gets radiosurgery
Radiosurgery is well suited to small-to-moderate, presumed grade I meningiomas that are growing or symptomatic, especially at surgically difficult sites (cavernous sinus, petroclival, tentorial), as well as to residual or recurrent tumor after subtotal resection and to tumors in elderly or comorbid patients. Imaging is contrast-enhanced MRI; somatostatin-receptor (DOTATATE) PET can aid delineation and confirm meningiomatous identity in ambiguous cases. Asymptomatic, non-growing meningiomas are often simply observed. Surgery remains preferred when there is significant mass effect or edema, when tissue diagnosis is needed, or for larger tumors amenable to safe resection.
Dose, Outcomes, and the Optic Constraint
2.Grade I dose and control
For presumed grade I meningioma, single-fraction marginal doses of roughly 12–16 Gy (commonly 13–15 Gy, prescribed at the 50% isodose line with Gamma Knife) achieve durable control, and the large series agree. The Pittsburgh experience (Kondziolka 2007, 972 patients, mean ~14 Gy) reported ~93% grade I control; the multicenter Santacroce series (~3,768 meningiomas, median 14 Gy) found 5- and 10-year progression-free survival of ~95% and ~89% overall, ~93%/83% for histologically confirmed grade I, and ~97%/93% for benign-imaging tumors treated without biopsy; and Pollock (416 grade I, median 16 Gy) reported 5- and 10-year local control of 96% and 89%. Notably, within the SRS-appropriate range tumor size does not reliably predict control — grade is the dominant determinant — and new cranial neuropathy is uncommon, with cavernous-sinus meningiomas showing excellent control alongside cranial-nerve preservation. The dominant constraint is the optic apparatus: for perioptic or juxta-optic tumors (cavernous sinus extending to the optic nerve/chiasm, optic-nerve-sheath meningioma), the single-fraction optic limit (~8–10 Gy) is often incompatible with a tumoricidal margin dose, so these are treated with fractionated SRT (or hypofractionation) to deliver adequate tumor dose within optic tolerance.
| WHO grade | Typical margin dose | Local control |
|---|---|---|
| Grade I (benign) | ~12–16 Gy (often 13–15) | ~90–96% at 5 yr, ~83–90% at 10 yr |
| Grade II (atypical) | ~16–18 Gy | ~50–65% at 5 yr |
| Grade III (anaplastic) | ~18 Gy | ~17–45%; SRS salvage/boost only |
3.Higher-grade meningioma is a different disease
Atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas recur far more readily and have infiltrative margins; single-fraction SRS to a tight margin is generally inadequate (5-year control falls to roughly 50–65% for grade II and lower for grade III, even at higher margin doses of ~16–18 Gy). These are managed with maximal safe resection and fractionated radiotherapy — typically on the order of ~54 Gy for grade II and ~59–60 Gy for grade III to generous margins — with the risk-adapted approach studied in RTOG 0539 and adjuvant grade II radiotherapy tested in EORTC 22042; SRS has a more limited, often salvage or boost, role for focal nodular recurrence. Recognizing that a "meningioma" may be higher grade — rapid growth, marked edema, bone invasion, atypical imaging — should prompt consideration of resection for diagnosis rather than empiric radiosurgery.
Decision Summary
| Scenario | Approach | Note |
|---|---|---|
| Small/moderate presumed grade I, difficult location | Single-fraction SRS ~12–15 Gy | ~85–95%+ long-term control; low new neuropathy |
| Cavernous sinus meningioma | SRS | Excellent control with cranial-nerve preservation |
| Perioptic / juxta-optic / optic-nerve-sheath | Fractionated SRT | Optic limit (~8–10 Gy single fx) precludes single-fraction margin |
| Atypical (grade II) / anaplastic (grade III) | Resection + fractionated RT (higher dose) | SRS limited/salvage role; RTOG 0539 framework |
| Asymptomatic, non-growing | Observation | Serial MRI |
Landmark Trials & Open Controversies
4.The evidence base, and the grade II problem
Meningioma radiosurgery rests on large prospective cohorts rather than randomized trials for grade I disease; the prospective trials concentrate on higher-grade tumors, where the real debates live.
| Study | What it established |
|---|---|
| Large GK cohorts (Kondziolka, Santacroce, Pollock) | Grade I control ~90–96% at 5 yr / ~83–90% at 10 yr at ~12–16 Gy margins |
| RTOG 0539 (phase II, risk-adapted) | Outcome benchmarks for low-, intermediate-, and high-risk meningioma by grade and resection |
| EORTC 22042-26042 | High-dose fractionated RT (~60 Gy) for atypical/anaplastic meningioma |
| ROAM / EORTC-1308 (ongoing) | Randomizes observation vs adjuvant RT after gross-total resection of atypical meningioma |
Open controversies:
- Adjuvant timing for grade II. Whether to irradiate immediately after resection or reserve radiation for documented recurrence is unresolved — the question ROAM is built to answer.
- SRS versus fractionated RT for atypical disease. Single-fraction SRS is limited for grade II/III tumors, which are infiltrative and larger; fractionated higher-dose RT (~54–60 Gy) is generally preferred, with SRS reserved for small, well-defined recurrences.
- Grading and the imaging diagnosis. Many SRS-treated meningiomas are never biopsied, so an unrecognized higher grade can masquerade as a benign-imaging tumor; the WHO 2021 molecular criteria are reshaping who is truly "grade I."
- Perioptic and large tumors. When a meningioma abuts the optic apparatus, the single-fraction optic limit forces fractionation — the same perioptic logic as the sellar region.
Key points
- SRS gives durable control of small/moderate presumed grade I meningiomas, especially skull-base, often without tissue diagnosis.
- Grade I marginal dose ~13–15 Gy (50% IDL) → ~90–96% / ~83–90% control at 5/10 yr (Kondziolka, Santacroce, Pollock); cavernous-sinus tumors do particularly well, and grade, not size, drives control.
- The optic apparatus caps single-fraction dose; perioptic/juxta-optic and optic-nerve-sheath tumors are treated with fractionated SRT.
- Atypical/anaplastic meningiomas are a different disease — resection + higher-dose fractionated RT (RTOG 0539 framework), not tight single-fraction SRS.
- Rapid growth, edema, or bone invasion should prompt resection for diagnosis rather than empiric radiosurgery; DOTATATE PET can aid delineation.
References
- Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821–1834. PubMed
- Marchetti M, Sahgal A, De Salles AAF, et al. Stereotactic radiosurgery for intracranial noncavernous sinus benign meningioma: International Stereotactic Radiosurgery Society systematic review, meta-analysis and practice guideline. Neurosurgery. 2020;87(5):879–890. PubMed
- Rogers CL, Won M, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018;129(1):35–47. PubMed
- Rogers CL, Won M, Vogelbaum MA, et al. High-risk meningioma: initial outcomes from NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020;106(4):790–799. PubMed
- Santacroce A, Walier M, Régis J, et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70(1):32–39. PMID 21746919
- Pollock BE, Stafford SL, Link MJ, et al. Single-fraction radiosurgery for presumed intracranial meningiomas: efficacy and complications from a 22-year experience. Int J Radiat Oncol Biol Phys. 2012. PubMed
Educational synthesis for neurosurgery and radiation-oncology trainees; doses and control ranges are representative, not a treatment directive. Guideline and trial references verified during review.